Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Asset Writedowns and Impairment: 2012-2025

Historic Asset Writedowns and Impairment for BIO-TECHNE (TECH) over the last 4 years, with Jun 2025 value amounting to $80.5 million.

  • BIO-TECHNE's Asset Writedowns and Impairment rose 428.46% to $84.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $115.1 million, marking a year-over-year increase of 123.87%. This contributed to the annual value of $80.5 million for FY2025, which is 266.54% up from last year.
  • BIO-TECHNE's Asset Writedowns and Impairment amounted to $80.5 million in FY2025, which was up 266.54% from $22.0 million recorded in FY2024.
  • Over the past 5 years, BIO-TECHNE's Asset Writedowns and Impairment peaked at $80.5 million during FY2025, and registered a low of $18.7 million during FY2022.
  • For the 2-year period, BIO-TECHNE's Asset Writedowns and Impairment averaged around $51.2 million, with its median value being $51.2 million (2024).
  • Data for BIO-TECHNE's Asset Writedowns and Impairment shows a peak YoY spiked of 266.54% (in 2025) over the last 5 years.
  • Yearly analysis of 3 years shows BIO-TECHNE's Asset Writedowns and Impairment stood at $18.7 million in 2022, then reached $22.0 million in 2024, then soared by 266.54% to $80.5 million in 2025.